Novel Rx
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
Dr. Jonathan Kay again leads an international panel of rheumatologists to elicit their opinions on key abstracts at ACR 2020. Panelists: Dr. David Liew, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway, Dr. Sheila Reyes and Dr. Jeffrey Sparks.
1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap
Dr. Petryna reviews several pegloticase-related abstracts presented at the ACR 2020 annual meeting, including abstracts #0683 and #0677.